Research location
Lisbon
Lisbon District, Portugal
Advertisement
Research activity in Lisbon
Lisbon District, PortugalCureCurrent currently publishes aggregate city-level research activity for this location: 57 trials and 72 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Lisbon
57 linked trials · page 1 of 2Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShuntNCT07359547 · 2026-01-01 · 1 site observation
RECRUITING
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 3 site observations
RECRUITING
More Health Less DiabetesNCT07079722 · 2025-09-01 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation
RECRUITING
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)NCT06961006 · 2025-05-29 · 1 site observation
RECRUITING
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24 · 1 site observation
RECRUITING
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)NCT06747949 · 2025-02-25 · 2 site observations
RECRUITING
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation
RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787 · 2024-09-26 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation
RECRUITING
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · 2024-04-03 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788 · 2023-12-15 · 2 site observations
RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)NCT05980949 · 2023-07-11 · 1 site observation
RECRUITING
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)NCT05714085 · 2023-05-31 · 1 site observation
RECRUITING
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation
RECRUITING
Family-centred Pulmonary Rehabilitation to Empower CarersNCT07791147 · 2026-09-01 · 1 site observation
NOT_YET_RECRUITING
PROMBot: A Web Platform for Collecting Outcomes for Hypertension Patients Via a ChatbotNCT06845007 · 2025-01-06 · 1 site observation
COMPLETED
Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)NCT06862479 · 2025-01-01 · 1 site observation
ENROLLING_BY_INVITATION
Exploring Unconventional Plant-Derived Metabolites for Glycemic Control: the Case of PomegranateNCT06659523 · 2024-06-01 · 1 site observation
COMPLETED
Immersive Meditation for Managing Preoperative Distress.NCT07785245 · 2024-01-31 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityNCT06104124 · 2024-01-24 · 1 site observation
COMPLETED
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16 · 2 site observations
ACTIVE_NOT_RECRUITING
Comparing Decision on Aesthetics After Breast Cancer Locoregional Treatment.NCT05196269 · 2023-08-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant TreatmentNCT05297773 · 2022-12-16 · 1 site observation
COMPLETED
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)NCT05189210 · 2022-10-05 · 1 site observation
COMPLETED
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)NCT05298423 · 2022-05-03 · 2 site observations
COMPLETED
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)NCT05224141 · 2022-03-24 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)NCT04961996 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · 2021-06-18 · 2 site observations
ACTIVE_NOT_RECRUITING
Anti-thrombotic and Glucose Lowering Therapy in Diabetic Patients Undergoing PCINCT04481997 · 2021-01-11 · 2 site observations
COMPLETED
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)NCT04624204 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)NCT04521621 · 2020-10-28 · 1 site observation
TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877 · 2019-10-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceNCT03223012 · 2017-11-15 · 4 site observations
COMPLETED
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsNCT03086343 · 2017-05-09 · 2 site observations
COMPLETED
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)NCT03061812 · 2017-04-11 · 1 site observation
COMPLETED
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)NCT03033511 · 2017-02-07 · 1 site observation
TERMINATED
Strategies for Revascularization in Patients Undergoing Heart Valve Surgery With Concomitant Coronary Artery DiseaseNCT02173860 · 2016-07-01 · 1 site observation
UNKNOWN
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)NCT02706951 · 2016-03-23 · 1 site observation
COMPLETED
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateNCT02706873 · 2016-02-23 · 2 site observations
COMPLETED
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsNCT02588261 · 2016-02-11 · 1 site observation
TERMINATED
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs AloneNCT02675426 · 2015-12-17 · 2 site observations
COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159 · 2015-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711 · 2015-08-24 · 1 site observation
COMPLETED
Optisure Lead Post Approval StudyNCT02235545 · 2014-08-01 · 1 site observation
TERMINATED
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)NCT01782326 · 2013-07-01 · 1 site observation
COMPLETED
Rehabilitation and Quality of Life in Residential Units for People With Longer Term Mental Health ProblemsNCT02366117 · 2012-04-01 · 1 site observation
UNKNOWN
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease PatientsNCT00998764 · 2009-12-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.